Drugs / BBT-207
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05920135 | Sep 2023 → Aug 2026 overdue | lung cancer | Bridge Biotherapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBT-207 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05920135 ↗ |
| Route | Oral | “BBT-207 given orally alone” NCT05920135 ↗ |